菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button
CRO Services

Drug Development Expertise Empowering Research Services for Biologics

Hybridoma


Accelerated Hybridoma Platform Compatible with Multiplexed Functional Assays

WuXi Biologics provides monoclonal antibody discovery services using our advanced hybridoma technology. We offer fully human antibody generation through transgenic animals, enabling high-quality therapeutic antibody discovery. With a proven track record of successfully delivering over 300 discovery projects, our expert team has developed cutting-edge techniques to maximize success rates from immunization to fusion & screening.

 

 

Key Features of Hybridoma Platform:

Immunization

  • AAALAC-accredited facilities ensuring ethical and high-quality animal care
  • Transgenic mice and rats for fully human antibody discovery
  • Tailored methods to overcome immune tolerance
  • Custom immunogen design and generation for diverse targets and applications, including DNAs, peptides, proteins, cells, and mRNAs

 

Fusion & Screening

  • High fusion efficiency using electrofusion technology
  • Over 4,000 single clones obtained directly from fusion
  • Subcloning skipped to save 2 weeks without compromising monoclonality
  • High-throughput screening platforms, including:
    • Binding assays using ELISA and FACS
    • Reporter gene assays (RGAs) for functional screening
    • Internalization assays supporting ADC development
  • High-throughput screening and ranking capabilities with 5 flow cytometers, 9 Biacore, and 1 Carterra.

Hybridoma Service Details:

Service Item Turnaround Time Request A Quote 
Immunization 4-12 weeks Request A Quote
Fusion & Screening 2-4 weeks
Hybridoma Sequencing 1-2 weeks

Case Study #1: Discovery and Characterization of a Therapeutic Monoclonal Antibody for ADC Development

High-throughput screening and in vitro characterization was conducted to identify and optimize monoclonal antibody with superior internalization, high-affinity binding, and effective cytotoxicity when conjugated to MMAE. Our hybridoma-based, high-throughput internalization screening and lead characterization assays enabled the selection of optimal ADC candidates with comparable or improved performance to benchmark antibodies.

 

Figure A: High-throughput screening of hybridoma-derived antibodies for internalization using the pHrodo assay. Herceptin demonstrated dose-dependent internalization in HER-2 expressing SK-BR-3 cells, serving as a positive control. FACS-based acid quenching internalization screening was used to compare to antibody 1 and antibody 2. Antibody 1 exhibited a higher internalization, making it a stronger candidate for ADC development.

Figure B: Internalization activity of lead antibodies compared to the benchmark (BMK1) in tumor cells, demonstrating comparable internalization efficiency. Dose-dependent epitope binning of lead antibodies with BMK1 confirmed antibodies with diverse binding epitopes are isolated from the screening campaign. Dose-dependent cytotoxicity of ADC candidates (Fab-MMAE conjugates) showed comparable cytotoxicity to the benchmark, confirming its potential for ADC therapeutics development.

Case Study #2: Discovery of a Monoclonal Antibody for Immunohistochemistry (IHC) Staining

We employed hybridoma discovery technology and characterization studies to identify high-affinity monoclonal antibodies for immunohistochemistry (IHC) applications. Using ELISA-based screening and IHC validation, our platform enabled the selection of optimal mAb candidates with high affinity and binding performance.

 

Figure A: Serum titer detection by ELISA, showing dose-dependent binding of antibodies against extracellular protein fragments of CD3. Mice were immunized with recombinant extracellular protein fragments to generate high-affinity monoclonal antibodies.

Figure B: Dose-dependent binding curves of mAbs against extracellular protein fragments of CD3, demonstrating strong and comparable binding activity between candidate 1 and candidate 2.

Figure C: Immunohistochemistry (IHC) staining results for two monoclonal antibody candidates at different concentrations. Candidate 1 displayed higher staining intensity and sensitivity compared to candidate 2, confirming its suitability for IHC staining applications.

Your Project. Our Expertise.